Hydrogen Bromide → 2-[4-[2-[4-(4-Pyridyl)piperazin-1-yl]acetyl]phenoxy]-isobutyric acid, dihydrobromide

HRID 1290511

Reaktionsgleichung

[N:1]1[CH:6]=[CH:5][C:4]([N:7]2[CH2:12][CH2:11][N:10]([CH2:13][C:14]([C:16]3[CH:29]=[CH:28][C:19]([O:20][C:21]([CH3:27])([CH3:26])[C:22]([O:24]C)=[O:23])=[CH:18][CH:17]=3)=[O:15])[CH2:9][CH2:8]2)=[CH:3][CH:2]=1.[BrH:30].O1CCOCC1>O>[BrH:30].[BrH:30].[N:1]1[CH:6]=[CH:5][C:4]([N:7]2[CH2:8][CH2:9][N:10]([CH2:13][C:14]([C:16]3[CH:29]=[CH:28][C:19]([O:20][C:21]([CH3:27])([CH3:26])[C:22]([OH:24])=[O:23])=[CH:18][CH:17]=3)=[O:15])[CH2:11][CH2:12]2)=[CH:3][CH:2]=1

Komponenten

Reaktionsbedingungen

Temperatur: 95 °C

Versuchsvorschrift

A mixture of methyl 2-[4-[2-[4-(4-pyridyl)piperazin-1-yl]acetyl]phenoxy]-isobutyrate (50 mg) 48% w/v hydrobromic acid (0.74 ml), dioxane (1 ml) and water (3 ml) was heated at 95° C. for 4 hours. The solution was cooled, diluted with water and freeze-dried to give the title compound, 40 mg, as a pale yellow solid: m.p. 163°-167° C.; NMR (D2O) δ8.40(2H,d), 8.16(2H,d), 7.40(2H,d), 7.21(2H,d), 5.21(2H,s), 4.32(4H,b), 3.89(4H,bt), 1.86(6H,s), m/e 384 (M+H)+ ; calculated for C21H25 N3.2HBr.2H2O: C, 43.3; H, 5.3; N, 7.2. found: C, 43.6; H, 5.3; N, 7.3%.

Aufarbeitung

temperatureThe solution was cooled
customfreeze-dried

Quellen und Nachweise

ORD-Eintrag: ord-f0d67188c93a43cfaec9c87846c85cc4
Quelldatensatz: uspto-grants-1998_05
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US05750754

Verknüpfte Notizen

Wird geladen…